Baum J
Scand J Rheumatol Suppl. 1979(28):65-70. doi: 10.3109/03009747909108240.
The use of penicillamine in the treatment of rheumatoid arthritis and scheroderma is reviewed. Much of the worlds literature was collected including both open studies and control studies. Both types with over 1,300 patients in the open trials and as one would expect, a smaller group in the control trials, showed about 64 percent of the patients having good results. Side effects range from one quarter to one third of the treated patients. This seems to show penicillamine as an effective drug for the treatment of rheumatoid arthritis though with a multiplicity of side effects. Its use in the treatment of scleroderma is still uncertain. Because of the rarity of the disease the number of patients treated has been small and the data is conflicting.
本文综述了青霉胺在类风湿性关节炎和硬皮病治疗中的应用。收集了世界上大部分文献，包括开放性研究和对照研究。在开放性试验中有超过1300名患者参与，正如预期的那样，对照试验中的患者数量较少，两类研究均显示约64%的患者取得了良好疗效。副作用发生率在接受治疗患者的四分之一到三分之一之间。这似乎表明青霉胺是一种治疗类风湿性关节炎的有效药物，尽管有多种副作用。其在硬皮病治疗中的应用仍不确定。由于该疾病罕见，接受治疗的患者数量较少，数据也相互矛盾。
